Modern medicine as we know it is threatened by antimicrobial resistance (AMR). From common surgeries to cancer treatments, drug-resistant pathogens are on track to undermine decades of medical advances and cause once treatable common infections and routine surgeries to be fatal – in fact infectious diseases are already the second leading cause of death for patients with cancer. Although clinicians, health policy professionals, governments, our industry and the public have recognized the rise of antimicrobial resistance as a growing threat, significant challenges remain in bringing innovative new drugs to patients. Hear from a panel of industry leaders discuss the challenges in innovation for AMR, the slow revision of guidelines and adoption of new improved treatments, possible approaches to address global accessibility, similarities to orphan and rare disease therapeutics, and use real world evidence for new agents.
